Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Applied Therapeutics (APLT) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$75000.0.

  • Applied Therapeutics' Cash from Financing Activities changed N/A to -$75000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$75000.0, marking a year-over-year decrease of 10005.24%. This contributed to the annual value of $113.8 million for FY2024, which is 5267.23% up from last year.
  • According to the latest figures from Q3 2025, Applied Therapeutics' Cash from Financing Activities is -$75000.0.
  • Applied Therapeutics' 5-year Cash from Financing Activities high stood at $115.5 million for Q1 2024, and its period low was -$1.7 million during Q2 2024.
  • Its 3-year average for Cash from Financing Activities is $26.9 million, with a median of $16.6 million in 2023.
  • The largest annual percentage gain for Applied Therapeutics' Cash from Financing Activities in the last 5 years was 1866864.95% (2024), contrasted with its biggest fall of 10580.43% (2024).
  • Applied Therapeutics' Cash from Financing Activities (Quarter) stood at $29.4 million in 2023, then plummeted by 105.75% to -$1.7 million in 2024, then surged by 95.57% to -$75000.0 in 2025.
  • Its Cash from Financing Activities was -$75000.0 in Q3 2025, compared to -$1.7 million in Q2 2024 and $115.5 million in Q1 2024.